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Taipei, TaiwanHepatocellular carcinoma (HCC) is the second leading cause
of cancer death inTaiwan.Theprimary liver cancer sequence
in Taiwan starts with chronic infection with hepatitis B virus
or hepatitis C virus, which is followed by cirrhosis and even-
tually the development of HCC. This is known as the trilogy of
liver disease. In recent years, more patients with HCC have
been diagnosed early and received curative treatment
because of the gradual implementation of regular liver ul-
trasound to screen and monitor populations at high risk for
developing HCC (e.g., patients with chronic hepatitis B,
chronic hepatitis C, and cirrhosis). Hence, the prognosis of
patients with HCC has improved substantially.
The selection of treatment modality for HCC is primarily
based on the practice guidelines proposed by the American
Association for the Study of Liver Diseases (AASLD) and the
European Association for the Study of the Liver (EASL). For
early stage HCC with the Barcelona Clinic Liver Cancer
(BCLC) staging classification stage 0, stage A, or for HCC
meeting the Milan Criteria (i.e., a solitary tumor smaller
than 5 cm or 2e3 nodules smaller than 3 cm), curative
treatment options include liver transplantation, surgical
resection, and local tumor ablation therapies. Local tumor
ablation therapies include percutaneous ethanol injection
therapy (PEIT), percutaneous acetic acid injection, percu-
taneous microwave coagulation, and radiofrequency abla-
tion (RFA). The 5-year survival rate exceeds 60% in patients
with early stage HCC [1,2].Conflicts of interest: The author declares no conflicts of
interest.
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therapies, RFA performs better in causing tumor necrosis,
compared to conventional PEIT. For tumors larger than 2
cm, it is noteworthy that the efficacy of RFA is significantly
better than the efficacy of PEIT with regard to fewer
treatment sessions, a higher rate of complete tumor ne-
crosis, less local recurrence, better overall survival rate,
and better recurrence-free survival rate [3]. Therefore,
RFA has become the most common first-line local tumor
ablation therapy for patients with small HCC.
The prognosis of patients with HCC after RFA is affected
by factors such as liver functional reserve (e.g., serum al-
bumin level, prothrombin time, and platelet count), age,
and tumor characteristics [e.g., tumor size, number,
vascular invasion, and serum alpha-fetoprotein (AFP) level]
[4,5]. A change in the serum AFP level after RFA provides a
clinical reference to tumor regression and recurrence [6,7].
In addition, in HCC patients with chronic hepatitis B or
hepatitis C, postoperative antiviral treatment can inhibit
viral replication, alleviate liver inflammation, regress
fibrosis, improve liver functional reserve, and increase pa-
tient’s survival [8]. Thus, it can be recommended as an
adjuvant therapy after RFA.
It is clinically important to compare the efficacy of RFA
with surgical resection in treating small HCC. In the past
few years, these treatments have been extensively inves-
tigated. According to studies published by the Taipei Vet-
erans General Hospital (Taipei, Taiwan) and Kaohsiung
Chang Gung Memorial Hospital (Kaohsiung City), which used
multivariate analysis and propensity score matching anal-
ysis, both treatment modalities provided comparable long-
term survival rates for patients with HCC within the Milan
Criteria; however, patients who received surgical resectionof Ultrasound in Medicine. Open access under CC BY-NC-ND license.
8 C.-W. Suhad lower tumor recurrence rates [9,10]. The current
practice guidelines by the AASLD, EASL, and the Asian Pa-
cific Association for the Study of the Liver for the man-
agement of HCC consequently all indicate that RFA and
surgical resection are the first-line treatments for early
stage HCC patients with good liver functional reserve [1,2].
However, surgical resection with its lower recurrence rate
generally provides slightly better outcomes, compared to
RFA. By contrast, RFA provides an ideal alternative if the
patient is older, has poor liver functional reserve or per-
formance status, or is unwilling to undergo surgery.
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